What MakeMyTrip (MMYT)'s Projected EPS and Revenue Growth Means For Shareholders

• In recent days, analysts reiterated that MakeMyTrip’s upcoming quarterly earnings are expected to show a 10.26% rise in earnings per share alongside a 17.3% increase in revenue compared with the same period last year.
• This combination of projected profit and sales growth, backed by stable analyst estimates and a Zacks Rank #3 (Hold), is reinforcing confidence in the company’s underlying business momentum.
• We’ll now explore how this expected earnings and revenue uplift could influence MakeMyTrip’s longer-term investment narrative and growth assumptions.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

MakeMyTrip Investment Narrative Recap

To own MakeMyTrip, you have to believe in the long term growth of online travel in India and the company’s ability to protect its position against intense competition and supplier pushback. The latest expectation of a 10.26% EPS rise and 17.3% revenue increase supports the near term catalyst of steady demand and monetization, but does not materially change the biggest risk right now: travel demand volatility from regional or macro shocks that can quickly hit bookings and margins.

Among recent developments, the launch of MakeMyTrip’s GenAI-powered Trip Planning Assistant, Myra, stands out in this context. If it helps deepen customer engagement and repeat usage, it could strengthen the company’s ability to defend its take rates and brand against global and domestic rivals, which is central to how investors think about both the earnings catalyst around this quarter and the longer term competitive risk profile.

But while earnings expectations look encouraging, investors should also be aware that...

Read the full narrative on MakeMyTrip (it's free!)

MakeMyTrip's narrative projects $1.8 billion revenue and $288.3 million earnings by 2028.

Uncover how MakeMyTrip's forecasts yield a $111.90 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span an extremely wide range, from about US$44.77 to over US$180,922.76 per share, highlighting just how far apart individual views can be. Against that backdrop, the current focus on projected EPS and revenue growth sits alongside persistent risks around volatile travel demand and heavy India exposure, which can materially influence how you interpret those diverse valuation views.

Explore 4 other fair value estimates on MakeMyTrip - why the stock might be a potential multi-bagger!

Build Your Own MakeMyTrip Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your MakeMyTrip research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free MakeMyTrip research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MakeMyTrip's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com